posit result
sale report strong number line
ms vent sale least part cushion impact lower
patient growth osa given alreadi strong perform ytd
stay ew
invest thesi ew us share price year date cdi
price vs close level februari see
note date trade consensu
thomson ep vs averag price target
premium valuat could remain long street continu believ
upsid relat ventil sale off-set potenti eros
base sleep apnea osa busi retain bull case
weight reflect street on-going focu vent proven otherwis
result juli
industri discuss result highlight follow strong
demand ventil row account almost
revenu beat vs ms ii us saw pull forward osa patient demand
march ahead social distanc measur meet robust growth
expect iii risk remain june/sept quarter suffer social
distanc though risk obviou number iv vent
yet make materi contribut us though chang markedli
iv likelihood increas lobbi delay detail see
 vi long-term prospect busi remain intact
could impact includ impact
forward estim detail within essenti larg upsw
vent sale may enough off-set drag osa sale
return pre financi
ms vs revenu ms ii gp margin
ms iii ep ms
us devic ms us masks/oth
ms row devic ms
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit statist resm cdi
price target convert cdi
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject finra restrict commun subject
compani public appear trade secur held
see two main impact busi pandem
slowdown new patient start cpap therapi would impact devic sale
lesser extent mask resuppli
upsid ventil
ventil repres small portion overal busi assum ventil
sale repres devic sale whole group
significantli lift product issu press releas march
ceo mick farrel said look doubl tripl output
ventil scale ventil mask product tenfold
april us depart human servic hh announc five
new contract ventil product hill-rom
 vyair award contract ventil produc
juli may june price million
april australian minist announc deliveri ventil
contract go toward
announc may result produc ventil
quarter though indic actual sale number
repres three-fold increas normal product increment sale relat
quarter split ventil remain
ventil mask
updat model captur impact higher ventil sale
march septemb quarter uplift vs pre estim shown
downsid cpap devic resuppli
industri dilig suggest slowdown new starter channel check
us base cpap supplier learnt demand product strong
month march howev gener expect slowdown april
onward mainli due slower doctor referr mani practic shut result
lockdown
impact mask resuppli sale expect devic replac
resuppli exist cpap patient continu given patient abl servic
remot receiv item mail estim devic sale
new patient major mask sale resuppli patient alreadi
therapi mean mask sale insul slowdown new patient
start devic
diagnosi doubl digit result said see signific impact
relat lockdown new patent diagnos sleep state doubl
digit declin diagnosi rate affect market assum cpap devic sale
fall quarter rel pre estim
exhibit cpap devic sale pre post
exhibit gp devic pre post
exhibit estim devic sale new patient
major mask sale resuppli patient alreadi
exhibit mask resuppli sale pre post
mask
exhibit impact revenu
exhibit impact gp
revenu vs mse driven stronger row sale
net incom ahead mse ahead ep
dp
impact higher demand ventil mask due
contribut sale revenu ex line mse
ventil bi-level devic tripl mask product expect
tailwind continu
saa digit health major focu call expect
acceler adopt matrixcar neg affect come quarter
sleep busi new patient start doubl digit affect market
resuppli sale increas look forward said uncertainti
whether upsid vent off-set declin cpap devic continu
strong mask growth said backlog diagnost activ
updat model result strong beat mse
updat near term forecast captur impact includ higher
ventil sale lower cpap devic mask sale
sg increas low singl digit high singl digit
low doubl digit tax rate next quarter expect
updat model captur updat outlook commentari
exhibit chang group level
exhibit chang segment
small increas base case
increas line base
neg ep revis off-set dcf
roll forward
increas line base
wide dispers outcom exist
price target set use blend methodolog appli bull-base-bear scenario
weight use bull case skew think market like pay
premium near term upsid ventil sale base case valu use dcf
methodolog wacc lt growth assumpt
rate ew
see long durat growth support
larg instal base growth ii
resuppli sale iii on-going oper
good ep certainti busi
momentum driven
share price excess price target
feel ew rate
view descript risk reward theme
us eu devic revenu growth
volum growth pa iv asp
pressur gm next year
higher longer ventil sale due
appli dcf valuat
forecast includ step us
growth rate associ new product
launch decay pa long term
reduct us mask price ii poc
remain market share iii
devic price iv resuppli volum
growth line devic growth
continu penetr obstruct sleep
high growth high-margin mask/dispos
china india
view explan region hierarchi
research highest favor quintil
higher market share cpap
faster-than-expect benet recent
round competit bid
higher ventil sale due
advers impact us competit bid
loss cpap market share
eur usd continu deterior
lower cpap devic resuppli sale due
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
wide dispers outcom exist
price target cdi deriv price target use ratio cdi
investor awar calcul take account issu risk
associ invest adr includ limit liquid vote right
dividend volatil currenc exchang rate uctuat
rate ew
see long durat growth support
larg instal base growth ii
resuppli sale iii on-going oper
good ep certainti busi
momentum driven
share price excess price target
feel ew rate
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
us devic growth higher current
forecast addit small move mask
turn see upsid poc reach
share higher longer ventil sale
appli dcf valuat
forecast includ step us
growth rate associ new product
launch decay pa long term
bear case assum reduct us
mask price reduct us unit growth
remain intern level pa
poc remain market share
continu penetr obstruct sleep
high growth high-margin mask/dispos
china india
view explan region hierarchi
higher market share cpap
faster-than-expect benet recent
round competit bid
higher ventil sale due
advers impact us competit bid
loss cpap market share
eur usd continu deterior affect
lower cpap devic resuppli sale due
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
compani data research research estim note provid research coverag list cdi associ
underli ordinari share compani courtesi may includ cdi price target cdi share price aud dollar research report unless otherwis state
cdi price target convers calcul use appropri currenc exchang rate ordinari share versu cdi ratio investor awar calcul
take account issu risk associ invest cdi includ limit liquid vote right dividend volatil currenc exchang rate fluctuat
